gefitinib has been researched along with Rhabdomyolysis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asano, K; Hayama, N; Ito, Y; Niimi, K; Obayashi, S; Oguma, T; Tanaka, J; Tomomatsu, K; Urata, M | 1 |
| Deng, Y; Sun, T; Wu, D; Zhang, D | 1 |
2 other study(ies) available for gefitinib and Rhabdomyolysis
| Article | Year |
|---|---|
Rhabdomyolysis Caused by Gefitinib Overdose.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Rhabdomyolysis | 2022 |
EGFR mediated the renal cell apoptosis in rhabdomyolysis-induced model via upregulation of autophagy.
Topics: Acute Kidney Injury; Animals; Apoptosis; Autophagy; ErbB Receptors; Gefitinib; Glycerol; Kidney; Mice; Myoglobin; Rhabdomyolysis; Up-Regulation | 2022 |